Nitric oxide (NO) is a physiologic signal essential to penile erection, and disorders that reduce NO synthesis or release in the erectile tissue are commonly associated with erectile dysfunction. NO synthase (NOS) catalyzes production of NO from L-arginine. While both constitutively expressed neuronal NOS (nNOS) and endothelial NOS (eNOS) isoforms mediate penile erection, nNOS is widely perceived to predominate in this role. Demonstration that blood-flow-dependent generation of NO involves phosphorylative activation of penile eNOS challenges conventional understanding of NO-dependent erectile mechanisms. Regulation of erectile function may not be mediated exclusively by neurally derived NO: Blood-flow-induced fluid shear stress in the penile vasculature stimulates phosphatidyl-inositol 3-kinase to phosphorylate protein kinase B, which in turn phosphorylates eNOS to generate NO. Thus, nNOS may initiate cavernosal tissue relaxation, while activated eNOS may facilitate attainment and maintenance of full erection.
Introduction
The discovery of nitric oxide (NO) as a major molecular regulator of penile erection about a decade ago has had a profound impact on the field of sexual medicine. The fact that NO signals the biochemical mechanism of corpus cavernosal tissue relaxation established an essential foundation for the development of phosphodiesterase-5 inhibitor therapy for the therapeutic management of erectile dysfunction (ED). Additional translational efforts to harness the potential of this molecule for therapeutic purposes have suggested other possible therapies including pharmacologic NO precursors or actual NO donors, [1] [2] [3] NO-based gene therapy, 4 ,5 derivatives of NO synthase (NOS)-associated regulatory proteins, 6 and compounds targeting other components of the NO-based signal transduction pathway. 7, 8 Ongoing basic scientific investigation of NO biology has revealed new concepts regarding the regulatory roles of this chemical, particularly those pertaining to mechanisms of activating NOS which synthesizes NO. In this brief review, the relatively new science of constitutive NOS activation via protein kinase phosphorylation is discussed, with particular attention given to its role in penile erection and to its possible therapeutic relevance for ED.
NO signal transduction
Current concepts in erection physiology support the role of NO as the principal mediator of penile erection operating through a specific signal transduction mechanism. [9] [10] [11] The molecule has a prominent messenger-signaling function, characterized by its release from nerves and endothelium in the cavernosal tissue and binding to soluble guanylyl cyclase in corporal smooth muscle cells, which results in the activation of the enzyme to produce the potent second messenger molecule, 3 0 , 5 0 -cyclic guanosine monophosphate (cGMP). This product then stimulates a cGMP-dependent protein kinase, protein kinase G (PKG), which critically induces the cavernosal tissue relaxant response.
The synthesis of NO depends upon the catalytic action of NOS and is derived from the precursor amino acid, L-arginine. The so-called constitutive NOS isoforms, neuronal NOS (nNOS) and endothelial NOS (eNOS), account for its controlled formation, which is physiologically relevant for penile erection, distinct from roles attributed to inducible NOS. These constitutive isoforms are regulated by classically known interactions played by the NOS regulatory cofactors, calcium, calciumbinding protein calmodulin, oxygen, and reduced NADPH. They generate NO transiently and in low amounts, consistent with traditional tenets of cellcell signaling, after a rise in intracellular calcium and calcium-calmodulin binding. This regulatory mechanism describes neural NO release upon neuronal depolarization in nNOS-containing nerve terminals in the penis, which relies on electrical impulses transmitted in response to psychogenic and reflexogenic erogenous stimuli. It also applies to eNOS-containing sinusoidal and penile vascular endothelium, which liberates endothelial NO upon local neurogenic stimulation by acetylcholine, and conceivably other agents such as substance P and bradykinin, transmitted from nerves making contact with the endothelium. Acute increases in 'shear stress,' the term used to indicate the mechanical forces of blood flow on the vascular lining, also supposedly drive rapid, but limited, amounts of NO release from eNOS by related biochemical mechanisms. 12 
Calcium-independent NOS activation
The biology of NO has evolved recently with descriptions of constitutive NOS activation depending less on calcium-calmodulin interactions. New investigative work confirms that physical stimuli and diverse biochemical signals, such as interactions with integrins, G proteins, and protein kinases, are capable of eliciting the long-term production of NO from endothelial sources. 12 An apparent mechanism for this observation subsequently was described in which such influences as chronic shear stress and various growth factors activate phosphatidylinositol-3-kinase (PI3-kinase) and its downstream effector, the serine/threonine protein kinase, protein kinase B (Akt), which in turn phosphorylates eNOS producing an activated state of the enzyme. [13] [14] [15] Thus, under some regulatory influences, eNOS is disposed to producing NO in a steady, not merely transient, fashion.
The phosphorylation of eNOS represents an important new area of investigation for the regulation of this enzyme ( Figure 1 ). Several precise sites for phosphorylation of eNOS under the influence of specific protein kinases have been identified. The phosphorylation of eNOS as activated by the PI3-kinase/Akt pathway occurs at the stimulatory site human Ser-1177 (bovine Ser-1179) in the enzyme's C-terminus region, reducing the enzyme's calcium dependence, increasing the rate of electron flux from the reductase domain to the oxygenase domain, and increasing the rate of NO formation. 13, 14, 16, 17 In contrast, the phosphorylation of eNOS at the inhibitory site human Thr-495 (bovine Thr-497) located in the calmodulin-binding sequence leads to deactivation of the enzyme by increasing its calcium-calmodulin dependence. 16, 18, 19 Importantly, since phosphorylation of eNOS at Ser-1177 is accompanied by dephosphorylation at Thr-495, and vice versa, the phosphorylation and dephosphorylation reactions at the two sites are thought to be coordinated [18] [19] [20] (Figure 1 ). Human Ser-1177 is the target of several protein kinases in addition to Akt, including AMP-activated protein kinase (AMPK), cAMP-dependent protein kinase (protein kinase A), PKG, and calmodulin II protein kinase. 21, 22 Phosphorylation at Thr-495 is mediated by protein kinase C. 18 Recent studies have confirmed additional regulatory sites including Ser-617 and Ser-635 (bovine sequences) in bovine aortic endothelial cells, which appear to exert important roles for mediating such eNOS-activating agonists as bradykinin, ATP, and vascular endothelial growth factor. 21 
Model of NOS-regulated erection
The constitutive NOS activation cascade has been further investigated in the regulation of the erectile response. Electrical stimulation of the cavernous nerve or direct injection of the vasorelaxant drug, papaverine, into the corpus cavernosum in rodent animal models results in rapid increases in phosphorylated Akt and eNOS. 23 Such effects, along with the erectile response from electrical stimulation and pharmacostimulation, are blocked by the intracavernosal administration of the PI3-kinase Figure 1 Signaling pathways controlling eNOS phosphorylation at Thr-497 and Ser-1197. 18 inhibitors, wortmannin and LY294002. 23 In mice lacking eNOS by targeted gene deletion, only attenuated erectile responses were observed after intracavernosal vasoactive drug administration. 23 Taken together, the results suggested that the PI3-kinase/Akt-induced eNOS phosphorylation mechanism operates under blood flow stimuli in the penis to sustain physiologic penile erection.
Such an NO signaling mechanism fits with the physiologic requirements of penile erection, occurring as a gradually occurring, hemodynamic event.
The described molecular mechanism also reconciles the concern that nerve endings in the penis likely discharge NO intermittently and in a finite distribution that is insufficient to exert a wide-ranging, NOregulated relaxant effect on the corpus cavernosum for producing full erection. Conceivably, the blood flow stimuli occurring at the initiation of erection coordinates a 'feed forward' process of blood flow in progressively more distal vascular tributaries, and expansion of sinusoidal spaces that augments NO release for signaling the widespread relaxation of the cavernosal tissue. Based on these precepts, a proposed model of NO-mediated erectile function fundamentally involves both nNOS and eNOS, whereby the former initiates the erectile response and the latter facilitates full erection (Figures 2 and  3) .
Further support for the phosphorylation of eNOS as a determinant of NO release was recently shown in the human corpus cavernosum. 24 Both Akt and the mitogen-activated protein (MAP) kinases 1 and 2 (extracellular signal-regulated protein kinases 1 and 2, (ERK 1/2)), which reduces eNOS activity, 25 are expressed prominently in the penile vascular endothelium and nerves with less pronounced localizations to smooth muscle. 24 Differences in immunostaining were identified for MAP kinase 1/2 (ERK 1/2) in the corporal smooth muscle of potent and impotent patients, with only the latter showing substantial expression. 24 The investigators speculated that this finding indicates a negative regulator role for MAP kinase 1/2 (ERK1/2) on eNOS in the penis, operating as a mechanism that contributes to ED. They were unable to identify differences between potent and impotent patients for Akt expression. 24 The discovery of novel pathways for NO production in the penis further underscores the essential effector role of NO in the physiologic and pharmacotherapeutic stimulation of the erectile response. The NO regulatory pathway influences other molecular mechanisms involved in penile erection, such as contractile factors of the adrenergic nervous system 26, 27 and the RhoA/Rho-kinase pathway. 28 In addition, the efficacy of phosphodiesterase-5 inhibitor therapy for ED relies significantly on upstream regulation by NO. While phosphodiesterase inhibitors prevent the degradation of the potent second messenger molecule cGMP, so that it accumulates to enhance corporal smooth muscle relaxation, NO production and release foremost drives the synthesis of cGMP. 29 
Future therapeutic considerations
The investigation of eNOS phosphorylation regulatory sites may have therapeutic relevance in the treatment of ED. Drugs that phosphorylate or dephosphorylate eNOS at sites leading to its activation (or inhibit eNOS phosphorylation or dephosphorylation at sites associated with its deactivation), or activate select upstream regulatory protein kinases favoring eNOS-dependent erectile responses could be clinically advantageous. Also, methods for gene transfer involving activated eNOS conceivably could offer therapeutic benefit. The idea that enhanced blood flow in the penile circulation causes NO release advances the possibility that therapies having vasostimulatory effects or angiogenic properties targeting eNOS could indeed be clinically useful to counter atherosclerotic or other vasculopathic derangements involving the penile vascular and cavernosal tissue. For that reason, the role of statins could be investigated beyond simple lipid reduction for the treatment or prevention of ED via eNOS activation in the penis, since these agents have been shown to stimulate Akt phosphorylation of eNOS in isolated vascular preparations. 30 Further developments in this research area may uncover a sound mechanistic basis to support the use of orally or locally vasoactive therapies for the improvement or restoration of penile health for etiologically obscure erectile disorders, such as those associated with aging and erectile inactivity. For instance, in the context of post-radical prostatectomy ED, the premise that early and repetitively administered pharmacotherapies rapidly recover postoperative erectile function would be supported further by scientific evidence that eNOS is activated with such regimens and revitalizes the cavernosal tissue.
Summary
Concepts of constitutive NOS regulation have evolved recently with the identification of calcium-independent regulatory interactions that determine eNOS activation, by which long-term production of NO occurs. These mechanisms appear to be relevant to the erectile response, with early scientific investigation confirming physiologic roles for phosphorylated constitutive eNOS in erectile function. Based on these precepts, a new understanding of NOSregulated penile erection is proposed according to which nNOS acts as the neurally directed initiator of penile erection and eNOS subserves a key bloodflow-dependent facilitative role in this physiologic activity. Constitutive NOS activation as a molecular mechanism involved in the regulation of penile erection may be exploited to further innovations in the treatment of ED.
Important questions
(1) Can pharmaceutical research develop a system to drive NO production at the endothelial level, in order to enhance the efficacy of PDE5 inhibitor therapy? Various options involving the phosphorylated eNOS activation cascade could be explored as possible approaches for this purpose. Specific eNOS-activating agonists, such as bradykinin, ATP, and vascular endothelial growth factor, could be investigated therapeutically while it may also be confirmed that such agonists exert effects on erection physiology through this mechanism.
Other drugs, and even gene therapy that leads to eNOS activation, may eventually be identified and investigated clinically. It is also interesting to consider whether frequent administration of vasoactive therapies for ED, which conceivably induces eNOS phosphorylation by promoting blood flow in the penile circulation, may serve as another nonspecific system to heighten NO production. Further research into such possibilities could then allow PDE5 inhibitor therapy to be used even more effectively than current roles that rely on basal endogenously produced NO. ( 2) It appears that a fundamental aspect of eNOS activation is the lowering of calcium that favors the catalytic activity of the enzyme. Are there therapeutic opportunities to drive NO production based on this requirement? Research findings suggest that calcium-mobilizing agonists promote eNOS enzyme activity by releasing the enzyme from intracellular protein elements, known as caveolae, that are associated with calcium-calmodulin-dependent activity. Release of this tonic inhibition of eNOS by such methods may represent an alternative approach for NO production. (3) The vascular literature describes laminar shear stress as having a protective effect, such as preventing atherosclerosis. The phosphorylated eNOS activation cascade has been proposed as the pathway for this effect. In light of the evidence that this cascade operates in the penis, is it possible for treatments based on this cascade to offer long-term benefits on cavernosal tissue health? Indeed, this cascade offers a pharmacotherapeutic target not just to promote physiologic vessel relaxation but also to inhibit apoptosis and to repress monocyte adhesion among molecular and cellular events promoted by atherogenic factors in the penile circulation.
